Multiple pharmacological approaches on Fibigia eriocarpa extracts by in vitro and computational assays

dc.contributor.authorZengin, Gökhan
dc.contributor.authorLobine, Devina
dc.contributor.authorMollica, Adriano
dc.contributor.authorLocatelli, Marcello
dc.contributor.authorCarradori, Simone
dc.contributor.authorMahomoodally, Mohamad Fawzi
dc.date.accessioned2020-03-26T19:54:45Z
dc.date.available2020-03-26T19:54:45Z
dc.date.issued2018
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractThe ethyl acetate, methanolic, and water extracts of Fibigia eriocarpa were assessed for a panoply of bioactivities. Total phenolic and flavonoid content were quantified as well as individual phenolic compounds by HPLC-DAD. The invitro antioxidant and enzyme (acetylcholinesterase (AChE), butyrylcholinesterase (BChE), tyrosinase, -amylase, and -glucosidase) inhibitory potential of the extracts were evaluated. In silico molecular docking was used to investigate possible interaction between dominant compounds and selected enzymes. Vanillin (303g/g extract), apigenin (270g/g extract), and kaempferol (180g/g extract) were the main compounds in the ethyl acetate extract, while the methanolic extract was characterized by the presence of vanillin, rutin, and apigenin (616, 616 and 252g/g extract, respectively). (+)-catechin (1422g/g extract) was the main compound in the water extracts. The ethyl acetate extract was found to be a superior source of antioxidant compounds and enzyme inhibitors against above-mentioned enzymes. Docking studies revealed that p-hydroxybenzoic and (+)-catechin have the best scores for tyrosinase, while kaempferol and apigenin showed the best binding pose for -glucosidase, AChE, and BChE. Results amassed herein are the first report on the phytochemical and biological attributes of F.eriocarpa, which tend to validate the pharmacological uses of this plant as an alternative medicine.en_US
dc.identifier.doi10.1111/fcp.12362en_US
dc.identifier.endpage413en_US
dc.identifier.issn0767-3981en_US
dc.identifier.issn1472-8206en_US
dc.identifier.issue4en_US
dc.identifier.pmid29505673en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage400en_US
dc.identifier.urihttps://dx.doi.org/10.1111/fcp.12362
dc.identifier.urihttps://hdl.handle.net/20.500.12395/36789
dc.identifier.volume32en_US
dc.identifier.wosWOS:000438025300006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofFUNDAMENTAL & CLINICAL PHARMACOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectantioxidanten_US
dc.subjectbioactive compoundsen_US
dc.subjectFibigiaen_US
dc.subjectmolecular dockingen_US
dc.subjectnatural enzyme inhibitorsen_US
dc.titleMultiple pharmacological approaches on Fibigia eriocarpa extracts by in vitro and computational assaysen_US
dc.typeArticleen_US

Dosyalar